Home » Topics » BioWorld Science

BioWorld Science
RSS

Oncternal opens enrollment in phase II portion of CIRLL study of cirmtuzumab plus ibrutinib

Aug. 7, 2019

Array BioPharma identifies new RET inhibitors

Aug. 7, 2019

New PI3K-delta inhibitors patented by Calitor Sciences, Sunshine Lake Pharma

Aug. 7, 2019

Enanta Pharmaceuticals discloses anti-hepatitis B virus compounds

Aug. 7, 2019

Indoleamine 2,3-dioxygenase 1 inhibitors discovered at Adlai Nortye

Aug. 7, 2019

Caspase-1 found to be protective in the pathogenesis of SLE

Aug. 7, 2019

Syros Pharmaceuticals describes new CDK7/cyclin H inhibitors

Aug. 7, 2019

Interim data reported from ongoing phase Ib study of EDP-1815 in psoriasis

Aug. 7, 2019

DKN-01 plus Keytruda shows positive clinical results in KEYNOTE-731 study

Aug. 7, 2019

IKM-5 demonstrates promising safety and efficacy in breast cancer models

Aug. 7, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...